# Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

> **NCT02462239** · NA · COMPLETED · sponsor: **Ontario Clinical Oncology Group (OCOG)** · enrollment: 292 (actual)

## Conditions studied

- Muscle-invasive Bladder Cancer

## Interventions

- **OTHER:** Whole-body FDG PET-CT

## Key facts

- **NCT ID:** NCT02462239
- **Lead sponsor:** Ontario Clinical Oncology Group (OCOG)
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-06
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-11-14
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2024-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462239, "Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT02462239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*